539 related articles for article (PubMed ID: 25504751)
1. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma.
Liu T; Sun Q; Li Q; Yang H; Zhang Y; Wang R; Lin X; Xiao D; Yuan Y; Chen L; Wang W
Mol Cancer Ther; 2015 Feb; 14(2):429-39. PubMed ID: 25504751
[TBL] [Abstract][Full Text] [Related]
2. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
[TBL] [Abstract][Full Text] [Related]
3. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma.
Yang F; Qian XJ; Qin W; Deng R; Wu XQ; Qin J; Feng GK; Zhu XF
PLoS One; 2013; 8(3):e59879. PubMed ID: 23533654
[TBL] [Abstract][Full Text] [Related]
4. PKI-587 enhances radiosensitization of hepatocellular carcinoma by inhibiting the PI3K/AKT/mTOR pathways and DNA damage repair.
Xie Y; Liu C; Zhang Y; Li A; Sun C; Li R; Xing Y; Shi M; Wang Q
PLoS One; 2021; 16(10):e0258817. PubMed ID: 34665844
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.
Mallon R; Feldberg LR; Lucas J; Chaudhary I; Dehnhardt C; Santos ED; Chen Z; dos Santos O; Ayral-Kaloustian S; Venkatesan A; Hollander I
Clin Cancer Res; 2011 May; 17(10):3193-203. PubMed ID: 21325073
[TBL] [Abstract][Full Text] [Related]
6. Chloroform extract from Sophora Tonkinensis Gagnep. inhibit proliferation, migration, invasion and promote apoptosis of nasopharyngeal carcinoma cells by silencing the PI3K/AKT/mTOR signaling pathway.
ShuoWang ; Song Z; Gong X; Ou C; Zhang W; Wang J; Yao C; Qin S; Yan B; Li Q; Wei K; Hou X; Zhou X; Miao J
J Ethnopharmacol; 2021 May; 271():113879. PubMed ID: 33524509
[TBL] [Abstract][Full Text] [Related]
7. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
8. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance.
Chang L; Graham PH; Hao J; Ni J; Bucci J; Cozzi PJ; Kearsley JH; Li Y
Cell Death Dis; 2013 Oct; 4(10):e875. PubMed ID: 24157869
[TBL] [Abstract][Full Text] [Related]
9. Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma.
Li W; Li J; Wang Y; Zhang K; Li N; Tian Z; Ni B; Wang H; Ruan Z
Oncotarget; 2016 Dec; 7(49):80586-80598. PubMed ID: 27811359
[TBL] [Abstract][Full Text] [Related]
10. Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.
Leiker AJ; DeGraff W; Choudhuri R; Sowers AL; Thetford A; Cook JA; Van Waes C; Mitchell JB
Clin Cancer Res; 2015 Jun; 21(12):2792-801. PubMed ID: 25724523
[TBL] [Abstract][Full Text] [Related]
11. Pre-treatment with angiotensin-(1-7) inhibits tumor growth via autophagy by downregulating PI3K/Akt/mTOR signaling in human nasopharyngeal carcinoma xenografts.
Lin YT; Wang HC; Chuang HC; Hsu YC; Yang MY; Chien CY
J Mol Med (Berl); 2018 Dec; 96(12):1407-1418. PubMed ID: 30374682
[TBL] [Abstract][Full Text] [Related]
12. The effects of PKI-402 on breast tumor models' radiosensitivity via dual inhibition of PI3K/mTOR.
Gasimli R; Kayabasi C; Ozmen Yelken B; Asik A; Sogutlu F; Celebi C; Yilmaz Susluer S; Kamer S; Biray Avci C; Haydaroglu A; Gunduz C
Int J Radiat Biol; 2023; 99(12):1961-1970. PubMed ID: 37389464
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma.
Wong CH; Loong HH; Hui CW; Lau CP; Hui EP; Ma BB; Chan AT
Invest New Drugs; 2013 Dec; 31(6):1399-408. PubMed ID: 23975511
[TBL] [Abstract][Full Text] [Related]
14. Anticancer effects of brusatol in nasopharyngeal carcinoma through suppression of the Akt/mTOR signaling pathway.
Guo S; Zhang J; Wei C; Lu Z; Cai R; Pan D; Zhang H; Liang B; Zhang Z
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1097-1108. PubMed ID: 32449143
[TBL] [Abstract][Full Text] [Related]
15. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
[TBL] [Abstract][Full Text] [Related]
16. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
[TBL] [Abstract][Full Text] [Related]
17. The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis.
Xiao Y; Yu Y; Jiang P; Li Y; Wang C; Zhang R
Cell Oncol (Dordr); 2020 Aug; 43(4):669-680. PubMed ID: 32382996
[TBL] [Abstract][Full Text] [Related]
18. Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt/mTOR and inducing oxidative stress.
Li Q; Ni W; Deng Z; Liu M; She L; Xie Q
Fundam Clin Pharmacol; 2017 Jun; 31(3):301-310. PubMed ID: 28078787
[TBL] [Abstract][Full Text] [Related]
19. PQR309, a dual PI3K/mTOR inhibitor, synergizes with gemcitabine by impairing the GSK-3β and STAT3/HSP60 signaling pathways to treat nasopharyngeal carcinoma.
Cao J; Zeng K; Chen Q; Yang T; Lu F; Lin C; Zhan J; Ma W; Zhou T; Huang Y; Luo F; Zhao H
Cell Death Dis; 2024 Mar; 15(3):237. PubMed ID: 38555280
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models.
Langdon SP; Kay C; Um IH; Dodds M; Muir M; Sellar G; Kan J; Gourley C; Harrison DJ
Sci Rep; 2019 Dec; 9(1):18742. PubMed ID: 31822716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
